top of page

National Patient Input and Research Opportunities identified by
Ontario Institute for Cancer Research (OICR)

  • A virtual Summit, Patients Redefining the Future of Health Care in Canada, will be taking place for a few hours per day across four days (November 14, 16, 17, & 18, 2022). This OICR Patient Community Welcome Webinar will include opening remarks from OICR's President and Scientific Director, Laszlo Radvanyi, an introduction to OICR and what we do from our Executive Vice President and Head of Implementation Science, Christine Williams, and an introduction to patient partnership at OICR from our Lead of Patient Partnership, Cassandra Bergwerff.  If you are interested in attending, please register for the event here.  For those of you unable to attend, don't worry! We will be recording the presentation portion of the webinar and posting it on our website following the event.

  • CONECTed (Collective Oncology Network for Exchange, Cancer care innovation, Treatment access and Education), a network of national oncology patient organizations in Canada, is undertaking a study to understand cancer patient experiences with using virtual care as a method of healthcare delivery during the COVID-19 pandemic. They are looking for interested individuals to participate in a one-on-one, phone-based, semi-structured interview about their experience with using virtual care as part of their cancer care during the COVID-19 pandemic. If you are interested in learning more, please find additional information in the file below.


  • Dr. Sophie Lebel’s Psychosocial Oncology Laboratory at the University of Ottawa is looking to adapt and provide a group intervention aimed at reducing fear of cancer recurrence in family caregivers of cancer survivors. They are offering one of these groups starting in the fall 2022 and are looking to recruit Canadian female family caregivers who would be interested in addressing their fear of cancer recurrence. For more information please send an email to for more information. 

2020 - Second $120,000 CVHLA and CRS Research Grant Announced!

Fundraising led by the Rick Bracey Memorial baseball tournament in Surrey BC and the Ontario Walk and Dance fundraising and the countless individual donations from across the country have allowed the CVHLA to put up a second $60,000 which will be spread over 2020 and 2021 for Canadian Cancer Research. Our partner, the Cancer Research Society (CRS), has matched this with their own $60,000.

Click here for details on the 2018 and 2020 grants.

Click here for details on the $480,000 in Canadian VHL research that has been generated due to our fundraising.

Canadian VHL Alliance (CVHLA) Research Funding

Since 2018 we have created $480,000 in Canadian VHL research grants with our partner the Cancer Research Society!

2020  - $120,000 Research Grant Partnership

In November of 2019 the Canadian VHL Alliance (CVHLA) has entered into a second partnership with The Cancer Research Society (CRS), a Canadian based organization that will match the $60,000 CVHLA donation, to create a $120,000 grant that was awarded to Dr. Sandra Turcotte in 2020.

2018  - $120,000 Research Grant Partnership

The first partnership between the CVHLA and the CRS in 2018 created a grant that was won by Dr. Najafabadi (see above for details) 

These prizes have attracted very high quality VHL related proposals that the CRS has also funded. Click here for more details

More about the Cancer Research Society (CRS)

In 2017 the Cancer Research Society has funded the following projects that are related to the VHL gene and/or ccRCC:

  • Dr. Ryan Russell, University of Ottawa: Characterization of VHL-mediated RB regulation in renal cancer

  • Dr. Stefan Taubert, The University of British Columbia (UBC): Exploring Mediator-dependent stress resistance as a new target (a protein acting downstream of VHL, in the same molecular pathway)

  • Dr. Yasser Riazalhosseini, McGill University: KDM5C mutations as determinants of sex-dependent therapy in renal cell carcinoma

  • Dr. Damu Tang, McMaster University:  Characterization of CYB5D2-mediated suppression of clear cell renal cell carcinoma (ccRCC)


Three grants on VHL were funded by the Cancer Research Society in the past years:

  • Sandra Turcotte, U of Moncton (2012-2014): The late-stage of autophagy: A role for the tumor suppressor gene von Hippel-Lindau in lysosomal degradation

  • Amin Pause, McGill University (2006-2008): The von Hippel-Lindau (VHL) protein suppresses angiogenesis by maintaining extracellular matrix integrity

  • Stephen Lee, University of Ottawa (2004-2006): Dissecting the oncogenic pathway of VHL loss kidney cancer

Our CVHLA goal is to apply a very large percentage of our donations directly to funding Research Projects.    

The video below describes a research project the US based VHL Alliance has funded. The CVHLA has supported these efforts in the past.

bottom of page